{"id":"14c-sb649868","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Orexin-1 and Orexin-2 receptors","explanation":"SB649868 is a dual orexin receptor antagonist that blocks the binding of orexin-A and orexin-B neuropeptides to their receptors. By inhibiting orexin signaling, which promotes wakefulness and arousal, the compound was investigated for its potential to treat insomnia and sleep disorders.","oneSentence":"Blocks both orexin-1 and orexin-2 receptors, inhibiting the wake-promoting effects of orexin neuropeptides in the brain."},"_scrapedAt":"2026-03-28T06:31:44.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123342,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"suvorexant","brand":"Belsomra","company":"Merck","rationale":"Approved dual orexin receptor antagonist for insomnia treatment"},{"name":"lemborexant","brand":"Dayvigo","company":"Eisai","rationale":"Approved dual orexin receptor antagonist for insomnia"},{"name":"daridorexant","brand":"Quviviq","company":"Idorsia","rationale":"Approved dual orexin receptor antagonist for insomnia"}],"description":"14C-SB649868 is a radiolabeled version of SB649868, a dual orexin receptor antagonist developed by GlaxoSmithKline. The carbon-14 labeled compound is used in Phase 1 clinical pharmacology studies to investigate the absorption, distribution, metabolism, and excretion (ADME) properties of the parent compound in humans.","indications":{"approved":[{"status":"investigational","condition":"Insomnia","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT00520663","phase":"PHASE1","title":"Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-08","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"14C-SB649868","genericName":"14C-SB649868","companyName":"GlaxoSmithKline","companyId":"gsk","firstApprovalDate":"","aiSummary":"14C-SB649868 is a small molecule used in a radiolabel study to determine its excretion, balance, and pharmacokinetics in healthy volunteers. It is being investigated for the treatment of Sleep Initiation and Maintenance Disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}